Literature DB >> 22088587

[Flavonoids of puerarin versus tanshinone II A for ischemic stroke: a randomized controlled trial].

Lei Chen1, Xiao-ying Bi, Li-xun Zhu, Yi-qing Qiu, Su-ju Ding, Ben-qiang Deng.   

Abstract

BACKGROUND: Flavonoids are widely used today in the treatment of ischemic stroke. The therapeutic effects and functions of flavonoids are, therefore, generating more and more interest.
OBJECTIVE: To investigate the therapeutic effects and functions of flavonoids of puerarin in treating patients with ischemic stroke. DESIGN, SETTING, PARTICIPANTS AND
INTERVENTIONS: A total of 67 inpatients suffering from ischemic stroke from the Department of Neurology, Changhai Hospital in China were divided into two groups randomly, the treatment group, which was treated with flavonoids of puerarin, and the control group, administered with tanshinone II A sulfate instead. MAIN OUTCOME MEASURES: Defects in neurological function were evaluated according to the National Institutes of Health Stroke Scale (NIHSS) on the first day of onset. Lactate dehydrogenase (LDH), serum interleukin-6 (IL-6) and brain-derived neurotrophic factor (BDNF) levels were determined by radioimmunoassay on the second trial day. After a 14-day treatment, LDH, serum IL-6 and BDNF levels and NIHSS score were also detected, and CT perfusion imaging was used to measure and analyze the regional cerebral blood flow (rCBF), regional cerebral blood volume (rCBV) and mean transit time (MTT).
RESULTS: On the first day, NIHSS scores of the two groups were similar. On the second day there was no significant difference in LDH and IL-6 levels between the treatment group and the control group. After a 14-day treatment, LDH and IL-6 levels and the NIHSS score in the treatment group were lower than those in the control group (P<0.05). There was no significant difference in BDNF levels in the two groups. After 14 d, the CT perfusion imaging demonstrated that the treatment group showed more effective blood perfusion than the control group.
CONCLUSION: Flavonoids of puerarin can restrain the increase of IL-6 after acute ischemic stroke, and depress the LDH raised by reperfusion after cerebral ischemia. It can also enhance blood perfusion of the ischemic region.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22088587     DOI: 10.3736/jcim20111109

Source DB:  PubMed          Journal:  Zhong Xi Yi Jie He Xue Bao        ISSN: 1672-1977


  4 in total

1.  Endorsement of CONSORT by Chinese medical journals: a survey of "instruction to authors".

Authors:  Lu Xiao; Jing Hu; Li Zhang; Hong-cai Shang
Journal:  Chin J Integr Med       Date:  2014-06-28       Impact factor: 1.978

Review 2.  Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado-Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies.

Authors:  Yu-Shuan Chen; Zhen-Xiang Hong; Shinn-Zong Lin; Horng-Jyh Harn
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

3.  Tanshinone IIA alleviates brain damage in a mouse model of neuromyelitis optica spectrum disorder by inducing neutrophil apoptosis.

Authors:  Ye Gong; Ya-Ling Zhang; Zhen Wang; Huan-Huan Song; Yuan-Chu Liu; Ao-Wei Lv; Li-Li Tian; Wen-Li Zhu; Ying Fu; Xiao-Li Ding; Lang-Jun Cui; Ya-Ping Yan
Journal:  J Neuroinflammation       Date:  2020-06-25       Impact factor: 8.322

4.  Puerarin partly counteracts the inflammatory response after cerebral ischemia/reperfusion via activating the cholinergic anti-inflammatory pathway.

Authors:  Xiaojie Liu; Zhigang Mei; Jingping Qian; Yongbao Zeng; Mingzhi Wang
Journal:  Neural Regen Res       Date:  2013-12-05       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.